Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels

Current Medical Research and Opinion

Volumn 24, Issue 3, 2008, Pages 815-819

  Hess, Gregory ^a,b,c   Hill, Jerrold ^a   Clough, Jeffrey ^b   Hulnick, Scott ^a   Nordyke, Robert J ^d  

^a Surveillance Data Inc   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d AMGEN INC   (United States)

Author keywords

Anemia; Cancer; Darbepoetin alfa; Prescribing patterns; Utilization

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG UTILIZATION; ELECTRONIC MEDICAL RECORD; EVALUATION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MYELODYSPLASTIC SYNDROME; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; DRUG UTILIZATION; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 41149174761     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X280383     Document Type: Article

References (21)

1. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006;3:CD003407
2. Amgen Inc. Aranesp (darbepoetin alfa) full prescribing information. [cited July 18, 2007]; Available from: www. aranesp.com/pdf/aranesp.pi.pdf
3. Amgen Inc. Epogen (erythropoetin alfa) full prescribing information. [cited July 18, 2007]; Available from: www. epogen.com/pdf/epogen_pi.pdf
4. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60
5. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72
6. Wright JR, Ung YC, Julian JA, Pritchard KI, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-32
7. National Comprehensive Cancer Network (NCCN). Cancer-and Treatment-Related Anemia. Version 2.2005. 2005
8. National Comprehensive Cancer Network (NCCN). Cancer-and Treatment-Related Anemia. Version 1.2006. 2006
9. National Comprehensive Cancer Network (NCCN). Cancer-and Treatment-Related Anemia Version 3.2007. 2007 [cited July 18, 2007]; Available from: www.nccn.org
10. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-107
11. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-16
12. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70
13. Musto P, Lanza F, Balleari E, Grossi A, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005;128:204-9
14. Stasi R, Abruzzese E, Lanzetta G, et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-risk myelodysplastic syndromes. Ann Oncol 2005;16:1921-7
15. National Comprehensive Cancer Network (NCCN). Myelodysplastic Syndromes. Version 1.2007. 2007 [cited March 28, 2007]; Available from: www.nccn.org
16. Phrommintikul A, Haas SJ, Elsik M; Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-8
17. United States Food and Drug Administration (FDA). Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA), [cited July 18, 2007]; Available from: www.fda.gov/ cder/drug/InfoSheets/HCP/RHE2007HCP.htm
18. Phurrough S, Jacques L, Ciccanti M, et al. Decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). Center for Medicare and Medicaid Services. July 30, 2007
19. Chase M, Matthews A. FDA Warning is a blow to Amgen. Wall Street Journal 2007 March 10, 2007
20. Pollack A. FDA Warning is issued on anemia drugs overuse. NY Times, 2007 March 10, 2007
21. Malin JL, Schneider EC, Epstein AM, et al. Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? J Clin Oncol 2006;24:626-34